[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Phraxis, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100604233","endoforce-post-approval-study-100604233",false,"NCT07146854","EndoForce Post Approval Study","Inclusion Criteria:\n\n* Patient is ≥18 years of age.\n* Patient requires the creation of a vascular access graft for hemodialysis, secondary to a diagnosis of ESRD.\n* Patient is able to have the vascular access ePTFE graft placed in an upper arm.\n* Patient or his\u002Fher legal guardian understands the study and is willing and able to comply with the dialysis schedule and follow-up requirements.\n* Patient or his\u002Fher legal guardian provides written informed consent.\n\nExclusion Criteria:\n\n* All contraindications for the EndoForce Connector System according to the IFU.\n* Patient is pregnant.\n* Patient is enrolled in another dialysis or vascular investigational study, without prior approval from the Sponsor.","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to collect long-term safety and performance data for the use of the EndoForce System for connecting a hemodialysis graft to a vein in patients with End Stage Renal Disease. This is not an experimental procedure or an experimental therapy. This means that the study device has been approved by the FDA.",[23],"End Stage Renal Disease (ESRD)",[25,26],"Hemodialysis","Arteriovenous graft","RECRUITING","2026-01-16",{"date":30,"type":31},"2026-01-21","ACTUAL",{"date":33,"type":31},"2026-01-13",{"date":35,"type":19},"2029-12",{"name":37,"class":38},"Phraxis, Inc.","INDUSTRY",2,""]